SCHEMBL29796895

SCHEMBL29796895

CC(C)(C)OC(=O)N[C@H]1CSc2cc(F)c(C(=O)NNC(=O)C3CN(C(=O)OCc4ccccc4)CC(F)(F)C3)cc2N(Cc2ccc(Cl)cc2)C1=O

nearest known ligand 0.35

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 4/20 0.35
▸ XIAP P98170 1/20 0.34
▸ POLB P06746 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ P2RX3 P56373 1/20 0.33
▸ PDE4B Q07343 1/20 0.33
▸ NPY1R P25929 1/20 0.32
▸ RORC P51449 2/20 0.32
▸ SCN9A Q15858 1/20 0.32
▸ GPBAR1 Q8TDU6 2/20 0.31
▸ PARP1 P09874 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ TP53 P04637 1/20 0.31
▸ HCRTR1 O43613 1/20 0.30
▸ HCRTR2 O43614 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26961789 1.00 SRC (0.35) SRCXIAPPOLBMAPTP2RX3
SCHEMBL26962024 0.94 SRC (0.36) SRCXIAPPOLBMAPTPDE4B
SCHEMBL26961629 0.91 TP53 (0.39) SRCXIAPMAPTNPY1RALDH1A1
SCHEMBL29796779 0.89 SRC (0.33) SRCXIAPPOLBMAPTP2RX3
SCHEMBL26961883 0.89 SRC (0.33) SRCXIAPPOLBMAPTP2RX3
SCHEMBL29796830 0.83 P2RX3 (0.33) POLBMAPTP2RX3
SCHEMBL26961909 0.83 P2RX3 (0.33) POLBMAPTP2RX3
SCHEMBL29796933 0.83 SRC (0.33) SRCXIAPPOLBMAPTP2RX3
SCHEMBL26962006 0.83 SRC (0.33) SRCXIAPPOLBMAPTP2RX3
SCHEMBL26962145 0.82 S1PR1 (0.33) SRCXIAPPOLBMAPTP2RX3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4291558-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2023-12-20 — — EP disclosed
WO-2022171745-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2022-08-18 — — WO disclosed
Send feedback